// App-Quantinova.ai

: Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

Researchers

Presenter

  • Julien Hadoux

Principal Investigators

  • Mimi I Hu

  • Marcia S. Brose

  • Elena Garralda

  • Christine Spitzweg

  • Noemí Reguart

  • Christine Do Cao

  • Martin D. Forster

  • Teresa Alonso-Gordoa

  • Teresa Barata

  • Astrid Scalori

  • Alena Zalutskaya

  • Peter Trask

  • Vivek Subbiah

Medical Centers

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Hospital Clinic Barcelona, Barcelona, Spain

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • UCL Cancer Institute, University College London,, London, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, United States.

  • Genentech Inc., San Francisco, United States

  • Gustave Roussy, Villejuif, France

  • Blueprint Medicines,Cambridge,United States

  • University Hospital, LMU Munich Deparmtne of Medicine III, Munich, Germany

  • Hopital Claude Huriez, Lille, France

  • Hospital Universitario Ramón Y Cajal, Universidad de Alcalá, Madrid, Spain

Locations

  • Switzerland

  • Spain

  • France

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Thyroid Cancer

Biomarkers

  • High affinity nerve growth factor receptor

Drug/Treatment

  • Cabozantinib

  • Vandetanib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT03037385

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved